{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"15","value":"6"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"11","value":"4.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"title":"Including imputations for participants who died"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"10","value":"5"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"7","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"72"}],"units":"Participants"}],"title":"Among participants who did not die"}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants who were not on non-invasive ventilation or high-flow oxygen use at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die","dispersionType":"Inter-Quartile Range","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEDIAN","populationDescription":"The analysis population is restricted to randomized participants who were not on non-invasive ventilation or high-flow oxygen at baseline but who subsequently required non-invasive or high-flow oxygen.","reportingStatus":"POSTED","timeFrame":"Day 1 through Day 29","title":"Duration of New Non-invasive Ventilation or High Flow Oxygen Use","type":"SECONDARY","unitOfMeasure":"Days"}